Related Experiment Video
Updated: Feb 27, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
18.0K
Thrombocytopenia induced by dabigatran: two case reports
Hyun Goo Kang1, Seung Jae Lee2, Ji Yeon Chung1
1Department of Neurology, Chosun University School of Medicine, Gwangju, 61453, Republic of Korea.
BMC Neurology
|July 1, 2017
Summary
Novel oral anticoagulants like dabigatran can cause thrombocytopenia, a dangerous drop in platelet count. Careful monitoring is crucial during dabigatran treatment to prevent this adverse effect.
Area of Science:
- Pharmacology
- Hematology
Background:
- Vitamin K inhibitors and heparin are standard anticoagulants but carry bleeding risks.
- Novel oral anticoagulants (NOACs) offer safer alternatives, with dabigatran directly inhibiting thrombin.
- While generally safe, rare cases suggest dabigatran may induce thrombocytopenia.
Observation:
- Two elderly patients developed severe thrombocytopenia and purpura after initiating dabigatran therapy.
- One patient experienced a drastic platelet drop to 6000/μL, while the other saw a significant decrease to 41,000/μL.
- Discontinuation of dabigatran led to platelet count recovery in both cases.
Findings:
- Dabigatran treatment was associated with acute thrombocytopenia and purpura in these cases.
- Platelet counts normalized within 14 days after discontinuing dabigatran.
- The mechanism may involve dabigatran's strong binding affinity to thrombin.
Implications:
- Close patient monitoring for thrombocytopenia is essential during dabigatran use.
- Understanding dabigatran's potential adverse effects is critical for safe anticoagulation management.
- Further research into the mechanism of dabigatran-induced thrombocytopenia is warranted.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:24Disorders of Hemostasis
2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
01:30Venous Thrombosis IV: Nursing Management
320
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
320